StocksMedium•5 November 2026•
1 min read
Schrödinger Amends Novartis Deal, Boosts Potential Milestone Payments to $1.424 Billion
Key Facts
1Schrödinger amended its existing collaboration with Novartis to replace previous programs with two new ones.
2Potential milestone payments under the amended agreement have increased to $1.424 billion.
Schrödinger amended its existing collaboration agreement with Novartis to replace previous programs with two new ones. Benzinga reported that potential milestone payments under the amended agreement have increased to $1.424 billion.
Schrödinger, trading under the ticker SDGR, closed at $28.52 on November 4, 2026, while Novartis (NVS) closed at $164.98 on the same date. The amendment aims to optimize the collaboration by focusing on new therapeutic programs while increasing the financial upside for Schrödinger.